Artificial Intelligence in COPD is transforming disease management, from underdiagnosis to treatment guidance. Discover how machine learning clusters patients, predicts outcomes, and optimizes healthcare resources.
Explore the causes of reduced FEV1 in early adulthood, with data from Lifelines and BAMSE cohorts. Findings highlight PRISm and airflow limitation origins, early identification in childhood, and differentiated clinical implications.
La Societat Catalana de Pneumologia (SOCAP) y Chiesi han lanzado la iniciativa ‘Sense Límits’ para concienciar sobre las enfermedades respiratorias, con actividades divulgativas y solidarias como espirometrías, pedaleos solidarios y marchas nórdicas, promoviendo la investigación científica y el cuidado de la salud respiratoria.
Explore the link between Preserved Ratio Impaired Spirometry (PRISm) and arterial stiffness, highlighting significant findings from the Austrian LEAD study. Learn how PRISm impacts cardiovascular health.
Discover the relationships between symptoms and lung function in asthma and COPD from the NOVELTY study, highlighting key spirometry measures and their impact.
Insight into the impact of doxycycline in therapeutic trials for COPD, emphasizing the need for careful microbiological monitoring in future interventional trials in patients with COPD
In the general population Persistent Airflow Obstruction (PAO) was largely mild but there are significant phenotypic differences between young and old individuals with PAO
Uncover the prevalence, characteristics, and comorbidities of asthma with airflow obstruction (AFO) in adults over 50. Learn how AFO compares to asthma-only and COPD-only in this comprehensive study.
The diagnosis of COPD requires the demonstration of non-fully reversible airflow limitation by spirometry in the appropriate clinical context.
The GOLD 2023 report identifies different causes (etiotypes) of COPD. Their prevalence in individuals in the general population with persistent airflow obstruction (PAO) is unknown.
